SCHEMBL828081

SCHEMBL828081

CC[Si](CC)(CC)OC=O

nearest known ligand 0.32

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.32
MAPK1 P28482 1/20 0.32
TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL15141778 0.97 ALDH1A1 (0.30) ALDH1A1MAPK1TDP1
SCHEMBL828054 0.77 ALDH1A1 (0.30) ALDH1A1
SCHEMBL11905988 0.75
SCHEMBL7895498 0.75 ALDH1A1 (0.32) ALDH1A1MAPK1TDP1
SCHEMBL11905111 0.73
SCHEMBL828184 0.73 TSHR (0.36)
SCHEMBL2345667 0.71
SCHEMBL7893172 0.69 TDP1 (0.30) TDP1
SCHEMBL828392 0.69 TSHR (0.41)
SCHEMBL828520 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020107414-A1 Method of prostaglandin synthesis ALCON RESEARCH, LTD. 2002-08-08 US claimed
US-11912731-B2 Use of silylated formiates as hydrosilane equivalents COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2024-02-27 US disclosed
WO-2023127869-A1 METHOD FOR PRODUCING N-ALKYL AMINO ACID AND PEPTIDE INCLUDING N-ALKYL AMINO ACID 中外製薬株式会社 2023-07-06 WO disclosed
WO-2021130848-A1 METHOD FOR PRODUCING SILYL ETHERIFIED PRODUCT OF POLYSACCHARIDE 国立大学法人金沢大学 2021-07-01 WO disclosed
EP-1950216-B1 PROCESS FOR PRODUCING ORGANIC TRANSITION METAL COMPLEX COMPOUND MITSUI CHEMICALS INC (JP) 2018-08-29 EP disclosed
US-9567354-B2 Amino acid-modified silane compounds and making method SHIN-ETSU CHEMICAL CO., LTD. (JP) 2017-02-14 US disclosed
EP-2687529-B1 CONDENSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL (JP) 2016-07-13 EP disclosed
US-9226921-B2 Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-05 US disclosed
US-9029388-B2 Condensed heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-12 US disclosed
US-8940758-B2 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-01-27 US disclosed
US-6291129-B1 LIGHT SENSITIVE ELEMENT WITH UNSATURATED POLYMERS KABUSHIKI KAISHA TOSHIBA (JP) 2001-09-18 US disclosed
WO-2000059513-A1 NON-CALCEMIC, ANTIPROLIFERATIVE, TRANSCRIPTIONALLY ACTIVE SULFUR-CONTAINING ANALOGS OF 1α, 25-DIHYDROXY VITAMIN D¿3? JOHNS HOPKINS UNIVERSITY (US) 2000-10-12 WO disclosed
WO-2000035941-A2 COMBINATORIAL PROCESS FOR PREPARING POLYAMINES MILLENNIUM PHARMACEUTICALS LIMITED (GB) 2000-06-22 WO disclosed
EP-0927175-A1 1-DEOXY BACCATIN III, 1-DEOXY TAXOL AND 1-DEOXY TAXOL ANALOGS AND METHOD FOR THE PREPARATION THEREOF FLORIDA STATE UNIVERSITY (US) 1999-07-07 EP disclosed
WO-1997042181-A1 1-DEOXY BACCATIN III, 1-DEOXY TAXOL AND 1-DEOXY TAXOL ANALOGS AND METHOD FOR THE PREPARATION THEREOF FLORIDA STATE UNIVERSITY (US) 1997-11-13 WO disclosed
US-4438265-A Esters of 7-sulfenyliminocephem-4-carboxylic acids SANKYO COMPANY LIMITED (JP) 1984-03-20 US disclosed
US-4162251-A Process for the preparation of β-lactam compounds SANKYO COMPANY LIMITED (JP) 1979-07-24 US disclosed
EP-0000644-A2 Lower cycloalkyl substituted-benzene derivatives, the preparation thereof and their pharmaceutical compositions FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1979-02-07 EP disclosed
US-4017488-A Process for preparing 7β-acylamino-7α-alkoxycephalosporins SANKYO COMPANY LIMITED (JA) 1977-04-12 US disclosed
US-3960845-A HALOGENATION SANKYO COMPANY LIMITED (JA) 1976-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912731-B2 Use of silylated formiates as hydrosilane equivalents PFAS, EPM2A, CYP2F1 ALDH1A1 112/4885MAPK1 2709/4885TDP1 2945/4885
US-20020107414-A1 Method of prostaglandin synthesis PTGIS, PTGS1, PTGES ALDH1A1 1474/4885MAPK1 3980/4885TDP1 3272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.